Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board Exonate Ltd., a biotechnology company developing novel
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the expansion of its Board with the appointment of Dr Rafiq Hasan as Non-Executive Director. Rafiq brings extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.
EXONATE APPOINTS DR RAFIQ HASAN AS NON-EXECUTIVE DIRECTOR Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens
In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.